Inhibikase Historical Financial Ratios

IKT Stock

USD 2.92 0.19 6.96%

Inhibikase Therapeutics is lately reporting on over 87 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.65 or Days Sales Outstanding of 111 will help investors to properly organize and evaluate Inhibikase Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

About Inhibikase Financial Ratios Analysis

Inhibikase TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Inhibikase Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Inhibikase financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Inhibikase Therapeutics history.

Inhibikase Therapeutics Financial Ratios Chart

At this time, Inhibikase Therapeutics' Income Quality is comparatively stable compared to the past year. EV To Operating Cash Flow is likely to gain to 0.10 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (2.54).

Price To Sales Ratio Days Sales Outstanding Average Payables Inventory Turnover Pfcf Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Inhibikase Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Inhibikase Therapeutics sales, a figure that is much harder to manipulate than other Inhibikase Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Inhibikase Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Inhibikase Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.At this time, Inhibikase Therapeutics' Income Quality is comparatively stable compared to the past year. EV To Operating Cash Flow is likely to gain to 0.10 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (2.54).

	2022	2023	2024 (projected)
Payables Turnover	0.00584	21.06	22.11
Days Of Inventory On Hand	60.7K	54.6K	57.3K

Payables Turnover Days Of Inventory On Hand

Inhibikase Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.03	-0.26	-0.36	0.46	0.43	0.02	0.52	-0.03	0.88	0.43	0.09	0.24	0.41	-0.22	-0.75	0.52	0.52	-0.29	-0.48	0.56	-0.52	-0.48	0.34	-0.35	0.14
Ptb Ratio	-0.03		0.44	0.68	-0.64	-0.8	0.86	-0.48	1.0	-0.38	-0.8	-0.79	-0.61	-0.78	0.61	0.46	-0.48	-0.48	0.71	0.56	-0.64	0.48	0.56	0.33	0.86	-0.8
Days Sales Outstanding	-0.26	0.44		0.16	-0.9	-0.65	0.22	-0.73	0.44	-0.62	-0.65	-0.57	-0.98	-0.54	0.98	0.61	-0.73	-0.73	0.08	0.47	-0.19	0.73	0.47	0.56	0.68	-0.63
Book Value Per Share	-0.36	0.68	0.16		-0.32	-0.79	0.75	-0.1	0.68	-0.56	-0.78	-0.45	-0.25	-0.7	0.26	0.28	-0.1	-0.1	0.99	0.56	-0.83	0.1	0.56	0.27	0.72	-0.47
Free Cash Flow Yield	0.46	-0.64	-0.9	-0.32		0.78	-0.35	0.92	-0.64	0.76	0.77	0.73	0.95	0.67	-0.93	-0.86	0.92	0.92	-0.26	-0.54	0.43	-0.92	-0.54	-0.27	-0.82	0.79
Operating Cash Flow Per Share	0.43	-0.8	-0.65	-0.79	0.78		-0.62	0.53	-0.8	0.75	1.0	0.72	0.74	0.89	-0.74	-0.63	0.53	0.53	-0.73	-0.62	0.83	-0.53	-0.62	-0.46	-0.96	0.76
Average Payables	0.02	0.86	0.22	0.75	-0.35	-0.62		-0.16	0.86	-0.29	-0.62	-0.45	-0.36	-0.72	0.36	0.18	-0.16	-0.16	0.81	0.71	-0.56	0.16	0.71	0.36	0.64	-0.47
Capex To Depreciation	0.52	-0.48	-0.73	-0.1	0.92	0.53	-0.16		-0.48	0.69	0.53	0.63	0.78	0.45	-0.76	-0.94	1.0	1.0	-0.06	-0.4	0.27	-1.0	-0.4	0.11	-0.62	0.69
Pb Ratio	-0.03	1.0	0.44	0.68	-0.64	-0.8	0.86	-0.48		-0.38	-0.8	-0.79	-0.61	-0.78	0.61	0.46	-0.48	-0.48	0.71	0.56	-0.64	0.48	0.56	0.33	0.86	-0.8
Ev To Sales	0.88	-0.38	-0.62	-0.56	0.76	0.75	-0.29	0.69	-0.38		0.75	0.39	0.62	0.69	-0.61	-0.83	0.69	0.69	-0.49	-0.7	0.67	-0.69	-0.7	-0.06	-0.69	0.46
Free Cash Flow Per Share	0.43	-0.8	-0.65	-0.78	0.77	1.0	-0.62	0.53	-0.8	0.75		0.72	0.74	0.89	-0.75	-0.62	0.53	0.53	-0.73	-0.62	0.83	-0.53	-0.62	-0.47	-0.96	0.76
Roic	0.09	-0.79	-0.57	-0.45	0.73	0.72	-0.45	0.63	-0.79	0.39	0.72		0.69	0.45	-0.68	-0.59	0.63	0.63	-0.41	-0.23	0.41	-0.63	-0.23	-0.24	-0.87	0.99
Inventory Turnover	0.24	-0.61	-0.98	-0.25	0.95	0.74	-0.36	0.78	-0.61	0.62	0.74	0.69		0.64	-1.0	-0.67	0.78	0.78	-0.19	-0.51	0.3	-0.78	-0.51	-0.53	-0.78	0.74
Net Income Per Share	0.41	-0.78	-0.54	-0.7	0.67	0.89	-0.72	0.45	-0.78	0.69	0.89	0.45	0.64		-0.64	-0.55	0.45	0.45	-0.69	-0.81	0.84	-0.45	-0.81	-0.41	-0.8	0.49
Days Of Inventory On Hand	-0.22	0.61	0.98	0.26	-0.93	-0.74	0.36	-0.76	0.61	-0.61	-0.75	-0.68	-1.0	-0.64		0.64	-0.76	-0.76	0.2	0.51	-0.3	0.76	0.51	0.57	0.78	-0.74
Payables Turnover	-0.75	0.46	0.61	0.28	-0.86	-0.63	0.18	-0.94	0.46	-0.83	-0.62	-0.59	-0.67	-0.55	0.64		-0.94	-0.94	0.23	0.48	-0.51	0.94	0.48	-0.21	0.67	-0.64
Average Inventory	0.52	-0.48	-0.73	-0.1	0.92	0.53	-0.16	1.0	-0.48	0.69	0.53	0.63	0.78	0.45	-0.76	-0.94		1.0	-0.06	-0.4	0.27	-1.0	-0.4	0.11	-0.62	0.69
Capex To Revenue	0.52	-0.48	-0.73	-0.1	0.92	0.53	-0.16	1.0	-0.48	0.69	0.53	0.63	0.78	0.45	-0.76	-0.94	1.0		-0.06	-0.4	0.27	-1.0	-0.4	0.11	-0.62	0.69
Cash Per Share	-0.29	0.71	0.08	0.99	-0.26	-0.73	0.81	-0.06	0.71	-0.49	-0.73	-0.41	-0.19	-0.69	0.2	0.23	-0.06	-0.06		0.58	-0.81	0.06	0.58	0.23	0.68	-0.43
Pocfratio	-0.48	0.56	0.47	0.56	-0.54	-0.62	0.71	-0.4	0.56	-0.7	-0.62	-0.23	-0.51	-0.81	0.51	0.48	-0.4	-0.4	0.58		-0.56	0.4	1.0	0.27	0.6	-0.27
Interest Coverage	0.56	-0.64	-0.19	-0.83	0.43	0.83	-0.56	0.27	-0.64	0.67	0.83	0.41	0.3	0.84	-0.3	-0.51	0.27	0.27	-0.81	-0.56		-0.27	-0.56	-0.11	-0.73	0.43
Capex To Operating Cash Flow	-0.52	0.48	0.73	0.1	-0.92	-0.53	0.16	-1.0	0.48	-0.69	-0.53	-0.63	-0.78	-0.45	0.76	0.94	-1.0	-1.0	0.06	0.4	-0.27		0.4	-0.11	0.62	-0.69
Pfcf Ratio	-0.48	0.56	0.47	0.56	-0.54	-0.62	0.71	-0.4	0.56	-0.7	-0.62	-0.23	-0.51	-0.81	0.51	0.48	-0.4	-0.4	0.58	1.0	-0.56	0.4		0.27	0.6	-0.27
Days Payables Outstanding	0.34	0.33	0.56	0.27	-0.27	-0.46	0.36	0.11	0.33	-0.06	-0.47	-0.24	-0.53	-0.41	0.57	-0.21	0.11	0.11	0.23	0.27	-0.11	-0.11	0.27		0.41	-0.26
Income Quality	-0.35	0.86	0.68	0.72	-0.82	-0.96	0.64	-0.62	0.86	-0.69	-0.96	-0.87	-0.78	-0.8	0.78	0.67	-0.62	-0.62	0.68	0.6	-0.73	0.62	0.6	0.41		-0.89
Roe	0.14	-0.8	-0.63	-0.47	0.79	0.76	-0.47	0.69	-0.8	0.46	0.76	0.99	0.74	0.49	-0.74	-0.64	0.69	0.69	-0.43	-0.27	0.43	-0.69	-0.27	-0.26	-0.89

Click cells to compare fundamentals

Inhibikase Therapeutics Account Relationship Matchups

Inhibikase Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	91.01	99.29	8.63	102.12	26.0	24.7
Ptb Ratio	(22.76)	7.09	0.7	0.6	0.62	0.65
Days Sales Outstanding	32.02	42.72	12.97	117.92	106.13	111.44
Book Value Per Share	(2.61)	5.84	12.66	5.01	2.06	2.05
Free Cash Flow Yield	(0.003311)	(0.0163)	(0.53)	(1.4)	(2.67)	(2.54)
Operating Cash Flow Per Share	(0.2)	(0.67)	(4.71)	(4.13)	(3.39)	(3.56)
Stock Based Compensation To Revenue	1.28	0.82	0.49	3.71	1.92	2.02
Pb Ratio	(22.76)	7.09	0.7	0.6	0.62	0.65
Ev To Sales	91.32	79.77	(4.43)	46.73	(6.8)	(6.46)
Free Cash Flow Per Share	(0.2)	(0.67)	(4.71)	(4.19)	(3.39)	(3.56)
Roic	1.39	(0.28)	(0.38)	(0.85)	(1.77)	(1.68)
Net Income Per Share	(3.34)	(1.72)	(4.88)	(4.26)	(3.57)	(3.75)
Payables Turnover	2.55	0.52	10.42	0.00584	21.06	22.11
Research And Ddevelopement To Revenue	2.27	1.28	3.66	97.5	52.28	54.89
Cash Per Share	0.0107	8.33	13.43	5.49	2.48	3.01
Pocfratio	(302.04)	(61.41)	(1.87)	(0.73)	(0.37)	(0.39)
Interest Coverage	(229.44)	(95.86)	(741.16)	(243.49)	(280.01)	(294.01)
Pfcf Ratio	(302.04)	(61.41)	(1.87)	(0.72)	(0.37)	(0.39)
Days Payables Outstanding	143.23	702.67	35.02	62.5K	17.33	16.47
Income Quality	0.0591	0.4	0.97	0.96	0.95	1.0
Roe	1.28	(0.29)	(0.39)	(0.85)	(1.73)	(1.65)
Ev To Operating Cash Flow	(303.09)	(49.33)	0.96	(0.33)	0.0979	0.1
Pe Ratio	(17.78)	(24.1)	(1.81)	(0.7)	(0.36)	(0.37)
Return On Tangible Assets	(150.25)	(0.19)	(0.35)	(0.72)	(1.31)	(1.38)
Ev To Free Cash Flow	(303.09)	(49.33)	0.96	(0.33)	0.0978	0.1
Earnings Yield	(0.0563)	(0.0415)	(0.55)	(1.42)	(2.81)	(2.67)
Current Ratio	0.008319	3.13	10.47	6.59	4.13	2.49
Tangible Book Value Per Share	(2.61)	5.84	12.66	5.01	2.06	2.05
Receivables Turnover	11.4	8.54	28.15	3.1	3.56	3.38
Graham Number	14.01	15.02	37.28	21.91	12.86	11.12
Shareholders Equity Per Share	(2.61)	5.84	12.66	5.01	2.06	2.05
Debt To Equity	(0.0833)	0.0326	0.006479	0.006933	0.0348	0.0365
Graham Net Net	(2.62)	5.35	12.14	4.7	1.82	1.72
Revenue Per Share	0.65	0.42	1.02	0.0294	0.0488	0.0464
Interest Debt Per Share	0.23	0.21	0.0886	0.0524	0.0716	0.068
Debt To Assets	9.77	0.0216	0.005861	0.005848	0.0263	0.025

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Inhibikase Historical Financial Ratios

About Inhibikase Financial Ratios Analysis

Inhibikase Therapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Inventory Turnover

Inhibikase Therapeutics fundamentals Correlations

Inhibikase Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibikase Therapeutics fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Inhibikase Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Average Inventory	+ 1.0	Capex To Depreciation
Capex To Revenue	+ 1.0	Capex To Depreciation
Capex To Revenue	+ 1.0	Average Inventory
Pfcf Ratio	+ 1.0	Pocfratio

Capex To Operating Cash Flow	- 1.0	Capex To Revenue
Capex To Operating Cash Flow	- 1.0	Average Inventory
Days Of Inventory On Hand	- 1.0	Inventory Turnover
Capex To Operating Cash Flow	- 1.0	Capex To Depreciation
Inventory Turnover	- 0.98	Days Sales Outstanding
Income Quality	- 0.96	Free Cash Flow Per Share